Covance

Clinical Research Associates- CoSource Poland

PL-Warsaw | PL
Job Number
2017-14261
Job Category
Clinical Research Associate
Position Type
Full-Time

Job Overview

CRA II / SCRA – ONCOLOGY

 

Summary:


CRA II position available to work directly through our CoSource division with a large Pharmaceutical company in the cutting edge area of Oncology, specifically immunotherapy. As an experienced CRA you’ll be involved in initiation, routine & close out visits. Successful candidates will enjoy the benefits of working for a company that values a WORK / LIFE BALANCE!

Covance Poland is certified as “HR of the Highest Quality”, which confirms the highest standards of HR practices in our Company.


USPs of CRA II role:


- Unlike some CRA roles you will not be pushed to satisfy unrealistic ‘monthly visit’ targets
- Join a stable team of CRAs across and benefit from outstanding training and development, both initially and throughout your career
- Join a company where people tend to stay for 6-10 years rather than 1-3!
- Join a genuinely friendly and supportive company where they allow individuals to take ownership of their own performance.
- ONCOLOGY Focussed

Other Information:
This role is a full time & permanent position employed through Covance.

Key words:
CRA II, GCP, Clinical Research Associate, Oncology, Warsaw, Poland, Clinical Monitor, Immunotherapy, Cancer Clinical trials

Education / Qualifications

CRA II:
- Ability to monitor Clinical study sites independently according to protocol monitoring guidelines, SOPs, GCP and ICH Guidelines
- Excellent understanding of Serious Adverse Event reporting
- Fluency in English and Polish

Experience

- Previous clinical research monitoring Experience (including pre-study, initiation, routine monitoring and closeout visits) in the Poland

Options

Sorry the Share function is not working properly at this moment. Please refresh the page and try again later.
Share on your newsfeed

Tell Us About Yourself

Not ready to apply? Connect with us to join our talent community.